drugset / Trial / NCT00956215
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
RandomizedParallel-groupDouble-blindPrevention
Summary
The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | — |
Indications
No indication recorded.